Abstract:Rheumatoid arthritis (RA) is an incurable chronic disorder that may induce autoinflammation and serious pain in the joints. Early diagnosis and treatment are important for RA prognosis. However, there is a lack of effective and objective diagnostic approaches. Levels of several immunity cytokines were found to change for patients with early RA, including IL-6, TNF-α, and IL-17 in serum. We assumed a combined change of these cytokines could predict early RA, and a total of 37 outpatients were found. After these patients with early symptoms had been followed for more than one year, 32 clinical cases of RA were diagnosed. The accuracy rate of the current method is >86%. We assumed the symptom relief could be achieved by regulating these cytokines and serum lipid-associated indicators. Thereafter, (R)-dihydrolipoic acid (R-DHLA)-stabilized gold nanoclusters (AuNCs) without (R-DHLA-AuNCs) and with cerium modification (R-DHLA-AuNCs-Ce) were employed for treatment of the RA rat model in vitro and in vivo. R-DHLA-AuNCs-Ce exhibited extraordinary reactive oxygen species-scavenging and anti-inflammation effects by regulating macrophage polarization, which was found to be more effective than methotrexate. The inflammation response of the joint microenvironment was also reduced with an exciting efficiency. By complex analysis of the pro-inflammatory cytokines and activity period indicators in vivo and in vitro, we concluded that macrophage-mediated inflammation exacerbated autoimmunity, which fully relieved the symptoms after administration of R-DHLA-AuNCs-Ce to RA rats.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c22831.Characteristic and unadjusted analysis of early RA (Tables S1 and S2), fatty acid and amino acid metabolites of early RA (Figure S1), material characterization of R-DHLA-AuNCs and R-DHLA-AuNCs-Ce (Figures S2–S9 and Table S3), quantification of the physical condition of CIA rats (Figure S10), quantification of the biochemical condition of CIA rats (Figure S11), stability of R-DHLA-AuNCs-Ce (Figures S12–S14), quantification of the Western blot analysis (Table S4), flow cytometric analysis of R-DHLA-AuNCs-Ce in ITI-treated macrophages (Figure S15), and detection of ROS scavenging (Figure S16) (PDF)This article has not yet been cited by other publications.

CRISPRa Engineered Elite Macrophages Enable Adoptive Cell Therapy for Rheumatoid Arthritis

Macrophage membrane-camouflaged biomimetic nanoparticles for rheumatoid arthritis treatment via modulating macrophage polarization

Targeted co-delivery biomimetic nanoparticles reverse macrophage polarization for enhanced rheumatoid arthritis therapy

A Targeted Exosome Therapeutic Confers Both Cfdna Scavenging and Macrophage Polarization for Ameliorating Rheumatoid Arthritis

Macrophage Membrane-Reversibly Cloaked Nanotherapeutics for the Anti-Inflammatory and Antioxidant Treatment of Rheumatoid Arthritis

Therapeutic Effects of IL-1RA, M2 Cells, and Their Synergistic Impact on a Mouse Model of Rheumatoid Arthritis

CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis

Genetically Engineered Biomimetic Nanoparticles for Targeted Delivery of mRNA to Treat Rheumatoid Arthritis

Extracellular vesicle-guided in situ reprogramming of synovial macrophages for the treatment of rheumatoid arthritis

Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy.

Genetically Engineered Macrophages Derived from iPSCs for Self-Regulating Delivery of Anti-Inflammatory Biologic Drugs

Engineered self-regulating macrophages for targeted anti-inflammatory drug delivery

Engineering Efferocytosis‐Mimicking Nanovesicles to Regulate Joint Anti‐Inflammation and Peripheral Immunosuppression for Rheumatoid Arthritis Therapy

Immuno-modulating theranostic gold nanocages for the treatment of rheumatoid arthritis in vivo

Remodeling articular immune homeostasis with an efferocytosis-informed nanoimitator mitigates rheumatoid arthritis in mice

Nanomedicines targeting activated immune cells and effector cells for rheumatoid arthritis treatment

Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms

Ultrasound-augmented anti-inflammatory exosomes for targeted therapy in rheumatoid arthritis

Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts

Nanomaterials Manipulate Macrophages for Rheumatoid Arthritis Treatment

Cytokine Regulation and Fast Inflammation Resolution in Early Rheumatoid Arthritis by Cerium-Modified Gold Nanoclusters